Literature DB >> 10994008

Apoptotic features accompany acute quadriplegic myopathy.

S Di Giovanni1, M Mirabella, A D'Amico, P Tonali, S Servidei.   

Abstract

OBJECTIVE: To investigate the role of apoptosis in acute quadriplegic myopathy.
BACKGROUND: Acute quadriplegic myopathy is a muscular disease characterized by diffuse flaccid weakness occurring in patients with severe systemic illness and exposure to corticosteroids or neuroblocking agents. Myofiber atrophy and thick filament loss are the distinguishing pathologic features on muscle biopsy. Increased calpains expression and lysosomal and nonlysosomal proteolytic pathways have been claimed as possible pathogenic factors. Nevertheless, the mechanisms leading to myofiber atrophy and thick filament loss need further investigation. PATIENTS AND METHODS: The expression of ubiquitin and proapoptotic proteases as well as DNA fragmentation in muscle biopsies from three patients with acute quadriplegic myopathy were studied.
RESULTS: All patients exhibited an important overexpression of caspases, calpain, cathepsin B, and ubiquitin, and the presence of numerous apoptotic nuclei in over 70% of myofibers.
CONCLUSIONS: These data suggest that apoptosis mediated by proteolytic proteases may play a role in the pathogenesis of acute quadriplegic myopathy.

Entities:  

Mesh:

Year:  2000        PMID: 10994008     DOI: 10.1212/wnl.55.6.854

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  [Cellular regulation of anabolism and catabolism in skeletal muscle during immobilisation, aging and critical illness].

Authors:  Eva-Maria Strasser; Barbara Wessner; Erich Roth
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 2.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

3.  Review of Critical Illness Myopathy and Neuropathy.

Authors:  Starane Shepherd; Ayush Batra; David P Lerner
Journal:  Neurohospitalist       Date:  2016-08-23

Review 4.  Critical illness polyneuropathy and myopathy in the intensive care unit.

Authors:  Wolfgang Zink; Rainer Kollmar; Stefan Schwab
Journal:  Nat Rev Neurol       Date:  2009-07       Impact factor: 42.937

Review 5.  Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients.

Authors:  Efstratios Apostolakis; Nikolaos A Papakonstantinou; Nikolaos G Baikoussis; George Papadopoulos
Journal:  J Anesth       Date:  2014-07-01       Impact factor: 2.078

Review 6.  Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective.

Authors:  C C Liu; J M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

7.  Distinct muscle apoptotic pathways are activated in muscles with different fiber types in a rat model of critical illness myopathy.

Authors:  Benjamin T Barnes; Amy L Confides; Mark M Rich; Esther E Dupont-Versteegden
Journal:  J Muscle Res Cell Motil       Date:  2015-03-05       Impact factor: 2.698

8.  Risk factors for physical impairment after acute lung injury in a national, multicenter study.

Authors:  Dale M Needham; Amy W Wozniak; Catherine L Hough; Peter E Morris; Victor D Dinglas; James C Jackson; Pedro A Mendez-Tellez; Carl Shanholtz; E Wesley Ely; Elizabeth Colantuoni; Ramona O Hopkins
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

9.  Participation of HSP27 in the antiapoptotic action of 17beta-estradiol in skeletal muscle cells.

Authors:  Andrea Vasconsuelo; Lorena Milanesi; Ricardo Boland
Journal:  Cell Stress Chaperones       Date:  2009-07-21       Impact factor: 3.667

10.  Myofibrillar protein and gene expression in acute quadriplegic myopathy.

Authors:  Holly Norman; Håkan Zackrisson; Yvette Hedström; Per Andersson; Jenny Nordquist; Lars I Eriksson; Rolf Libelius; Lars Larsson
Journal:  J Neurol Sci       Date:  2009-06-06       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.